Nice post. I'm getting sick of people hyping up crazy good first-line numbers and then calling for a huge sell off if we don't make that inflated goal.
I wrote an e-mail previously in which I had presented a much better comparison trial for the old phase 2a first-line NSCLC trial instead of using the Avastin + CP first-line trial, as done by Peregrine in their PR. This shows that an increase in MOS of 40-50% is reasonable for the current phase 2b first-line NSCLC, assuming the control and treatment arms are balanced. http://investorshub.advfn.com/boards/read_msg.aspx?message_id=83747030